PT  - JOURNAL ARTICLE
AU  - Gomes, M. Gabriela M.
AU  - Aguas, Ricardo
AU  - King, Jessica G.
AU  - Langwig, Kate E.
AU  - Souto-Maior, Caetano
AU  - Carneiro, Jorge
AU  - Penha-Gonçalves, Carlos
AU  - Gonçalves, Guilherme
AU  - Ferreira, Marcelo U.
TI  - Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold
AID  - 10.1101/2020.04.27.20081893
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.04.27.20081893
4099  - http://medrxiv.org/content/early/2021/08/01/2020.04.27.20081893.short
4100  - http://medrxiv.org/content/early/2021/08/01/2020.04.27.20081893.full
AB  - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began to spread in late 2019, gradually depleting susceptible populations and causing the incidence of new infections to decline over time. Variation in individual susceptibility or exposure to infection exacerbated this effect. Individuals who were more susceptible or more exposed tended to be infected earlier, depleting the susceptible subpopulation of those who were at higher risk of infection. This selective depletion of susceptibles intensified the deceleration in incidence irrespectively of vaccination programmes. In a theoretical scenario of acquired immunity being long-lasting, susceptible numbers would eventually become low enough to prevent epidemic growth or, in other words, the herd immunity threshold (HIT) would be naturally reached. Early in the coronavirus disease (COVID-19) pandemic, simple calculations, relying on homogeneity assumptions, suggested that herd immunity would require 60-80% of the population to become immune. Here we build, into the underlying models, individual variation in susceptibility or in exposure to infection and demonstrate how that lowers the HIT. Based on data from a variety of sources and early parameter estimates these basic models suggest the HIT associated with natural infection to be in the order of 10-30% for SARS-CoV-2. We discuss how a structure accounting for unobserved selectable variation can be a core feature of infectious disease modelling embedded in model development as reality evolves and complexity is incremented. The goal is to enhance accuracy and enable trade-offs to be adequately addressed in the design of optimal policies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are publicly available.